Study details
Enrolling now
Evaluating Depemokimab Early Therapy in COPD
GlaxoSmithKline
NCT IDNCT07177339ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
1,196
Study length
about 4.2 years
Ages
40–75
Locations
1 site in FL
About this study
Researchers are testing whether early treatment with depemokimab, added to standard care, improves outcomes for people with moderate to severe COPD and type 2 inflammation. The trial will last about 1500 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Depemokimab
- 2.Take Placebo
PhasePhase 3
DrugDepemokimab
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
monoclonal antibody
Endpoints
Secondary: Change from Baseline in Evaluating Respiratory Symptoms (E-RS): COPD Total Score at Week 52, Change from Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
Body systems
Respiratory